Home

Laurie Stelzer

CIK 1644348 · Chief Financial Officer · last filed 2026-06-18

Laurie Stelzer is a Chief Financial Officer who has filed 49 SEC Form 4 insider transactions across 9 companies since 2015. The most recent filing, for SION, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$172.6K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

9

Total Filings

49

Lifetime Open-Market Net

$172.6K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SION Director — $46.55 — $0 2 2026-06-18
PMVP Director — $1.10 — $0 6 2026-06-05
MBX Director — $60.06 — $0 2 2026-06-05
SYRE Director — $99.96 — $0 3 2026-05-29
Spyre Therapeutics, Inc. (AGLE) Delisted Director — $12.01 — $0 1 2023-11-27
Mirati Therapeutics, Inc. (MRTX) Delisted Chief Financial Officer 102,312 $58.70 $6.01M -$172.2K 4 2023-08-10
Surface Oncology, Inc. (SURF) Delisted Director — $1.07 — $0 4 2022-06-10
ARENA PHARMACEUTICALS INC (ARNA) Delisted EVP & Chief Financial Officer 28,122 $99.99 $2.81M $0 5 2022-03-11
HALOZYME THERAPEUTICS, INC. (HTI) Delisted SVP, Chief Financial Officer 126,167 — — $344.8K 22 2020-02-24

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 SION Grant (A) — $0 EDGAR
2026-06-05 PMVP Grant (A) — $0 EDGAR
2026-06-05 MBX Grant (A) — $0 EDGAR
2026-05-29 SYRE Grant (A) — $0 EDGAR
2026-01-22 MBX Grant (A) — $0 EDGAR
2025-06-16 SION Grant (A) — $0 EDGAR
2025-06-09 PMVP Grant (A) — $0 EDGAR
2025-06-02 SYRE Grant (A) — $0 EDGAR
2024-06-10 PMVP Grant (A) — $0 EDGAR
2024-05-16 SYRE Grant (A) — $0 EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.